Skip to main content
. Author manuscript; available in PMC: 2022 Feb 20.
Published in final edited form as: Free Radic Biol Med. 2021 Jan 6;164:34–43. doi: 10.1016/j.freeradbiomed.2020.12.445

Figure 5.

Figure 5.

Preventing accumulation of senescent cells mediates fibrosis. A. Timelines of two treatment protocols used. 2-hours pre-treatment with 30µm quercetin prior to UVA (top), and 5-hours 200nm dasatinib + 30µm quercetin (DQ) treatment 24-hours post-UVA (bottom). B. Intracellular ROS analysis for untreated, UVA treated, and quercetin + UVA. **P < 0.01, *P < 0.05 (n=3). C. mRNA levels for untreated, UVA treated, and UVA + quercetin pre-treatment, expressed as fold change vs untreated. ***P < 0.001 (n=3). D. SA-β-GAL staining for each treatment group. E. Quantification of SA-β-GAL positive cells in each treatment group. ***P < 0.001 (n=3, with 10 random areas analyzed in each sample). F. mRNA levels for untreated, UVA treated, and UVA + DQ treatment, expressed as fold change vs untreated. ***P < 0.01, **P < 0.01, *P < 0.05. Data presented as mean values ± SE. Scale bars = 100µm.